Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 28, p.4685-92 (2009)


2009, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cancer Vaccines, Center-Authored Paper, Clinical Research Division, Combined Modality Therapy, Fatigue, Female, Headache, Humans, Kaplan-Meier Estimate, Middle Aged, Molecular Sequence Data, Neoplasm Metastasis, Pain, Peptides, Public Health Sciences Division, Receptor, erbB-2, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, T-Lymphocytes, Transforming Growth Factor beta, Treatment Outcome, Vaccination


The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer.